114 related articles for article (PubMed ID: 10194128)
1. CRKL binding to BCR-ABL and BCR-ABL transformation.
Kolibaba KS; Bhat A; Heaney C; Oda T; Druker BJ
Leuk Lymphoma; 1999 Mar; 33(1-2):119-26. PubMed ID: 10194128
[TBL] [Abstract][Full Text] [Related]
2. Direct binding of CRKL to BCR-ABL is not required for BCR-ABL transformation.
Heaney C; Kolibaba K; Bhat A; Oda T; Ohno S; Fanning S; Druker BJ
Blood; 1997 Jan; 89(1):297-306. PubMed ID: 8978305
[TBL] [Abstract][Full Text] [Related]
3. The CRKL adaptor protein transforms fibroblasts and functions in transformation by the BCR-ABL oncogene.
Senechal K; Halpern J; Sawyers CL
J Biol Chem; 1996 Sep; 271(38):23255-61. PubMed ID: 8798523
[TBL] [Abstract][Full Text] [Related]
4. Tyrosine 207 in CRKL is the BCR/ABL phosphorylation site.
de Jong R; ten Hoeve J; Heisterkamp N; Groffen J
Oncogene; 1997 Feb; 14(5):507-13. PubMed ID: 9053848
[TBL] [Abstract][Full Text] [Related]
5. p130CAS forms a signaling complex with the adapter protein CRKL in hematopoietic cells transformed by the BCR/ABL oncogene.
Salgia R; Pisick E; Sattler M; Li JL; Uemura N; Wong WK; Burky SA; Hirai H; Chen LB; Griffin JD
J Biol Chem; 1996 Oct; 271(41):25198-203. PubMed ID: 8810278
[TBL] [Abstract][Full Text] [Related]
6. Identification of CRKL as the constitutively phosphorylated 39-kD tyrosine phosphoprotein in chronic myelogenous leukemia cells.
Nichols GL; Raines MA; Vera JC; Lacomis L; Tempst P; Golde DW
Blood; 1994 Nov; 84(9):2912-8. PubMed ID: 7524758
[TBL] [Abstract][Full Text] [Related]
7. Cellular interactions of CRKL, and SH2-SH3 adaptor protein.
ten Hoeve J; Kaartinen V; Fioretos T; Haataja L; Voncken JW; Heisterkamp N; Groffen J
Cancer Res; 1994 May; 54(10):2563-7. PubMed ID: 8168080
[TBL] [Abstract][Full Text] [Related]
8. Engagement of the CrkL adaptor in interferon alpha signalling in BCR-ABL-expressing cells.
Grumbach IM; Mayer IA; Uddin S; Lekmine F; Majchrzak B; Yamauchi H; Fujita S; Druker B; Fish EN; Platanias LC
Br J Haematol; 2001 Feb; 112(2):327-36. PubMed ID: 11167825
[TBL] [Abstract][Full Text] [Related]
9. CRKL links p210BCR/ABL with paxillin in chronic myelogenous leukemia cells.
Salgia R; Uemura N; Okuda K; Li JL; Pisick E; Sattler M; de Jong R; Druker B; Heisterkamp N; Chen LB
J Biol Chem; 1995 Dec; 270(49):29145-50. PubMed ID: 7493940
[TBL] [Abstract][Full Text] [Related]
10. Interactions of CBL with BCR-ABL and CRKL in BCR-ABL-transformed myeloid cells.
Bhat A; Kolibaba K; Oda T; Ohno-Jones S; Heaney C; Druker BJ
J Biol Chem; 1997 Jun; 272(26):16170-5. PubMed ID: 9195915
[TBL] [Abstract][Full Text] [Related]
11. The BCR/ABL oncogene alters interaction of the adapter proteins CRKL and CRK with cellular proteins.
Uemura N; Salgia R; Li JL; Pisick E; Sattler M; Griffin JD
Leukemia; 1997 Mar; 11(3):376-85. PubMed ID: 9067577
[TBL] [Abstract][Full Text] [Related]
12. The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway.
Sattler M; Salgia R; Okuda K; Uemura N; Durstin MA; Pisick E; Xu G; Li JL; Prasad KV; Griffin JD
Oncogene; 1996 Feb; 12(4):839-46. PubMed ID: 8632906
[TBL] [Abstract][Full Text] [Related]
13. Crkl is complexed with tyrosine-phosphorylated Cbl in Ph-positive leukemia.
de Jong R; ten Hoeve J; Heisterkamp N; Groffen J
J Biol Chem; 1995 Sep; 270(37):21468-71. PubMed ID: 7545163
[TBL] [Abstract][Full Text] [Related]
14. A specific need for CRKL in p210BCR-ABL-induced transformation of mouse hematopoietic progenitors.
Seo JH; Wood LJ; Agarwal A; O'Hare T; Elsea CR; Griswold IJ; Deininger MW; Imamoto A; Druker BJ
Cancer Res; 2010 Sep; 70(18):7325-35. PubMed ID: 20807813
[TBL] [Abstract][Full Text] [Related]
15. Cell-penetrating SH3 domain blocker peptides inhibit proliferation of primary blast cells from CML patients.
Kardinal C; Konkol B; Schulz A; Posern G; Lin H; Adermann K; Eulitz M; Estrov Z; Talpaz M; Arlinghaus RB; Feller SM
FASEB J; 2000 Aug; 14(11):1529-38. PubMed ID: 10928987
[TBL] [Abstract][Full Text] [Related]
16. Interactions of p62(dok) with p210(bcr-abl) and Bcr-Abl-associated proteins.
Bhat A; Johnson KJ; Oda T; Corbin AS; Druker BJ
J Biol Chem; 1998 Nov; 273(48):32360-8. PubMed ID: 9822717
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine phosphorylation of p120cbl in BCR/abl transformed hematopoietic cells mediates enhanced association with phosphatidylinositol 3-kinase.
Jain SK; Langdon WY; Varticovski L
Oncogene; 1997 May; 14(18):2217-28. PubMed ID: 9174058
[TBL] [Abstract][Full Text] [Related]
18. LASP1 is a novel BCR-ABL substrate and a phosphorylation-dependent binding partner of CRKL in chronic myeloid leukemia.
Frietsch JJ; Kastner C; Grunewald TG; Schweigel H; Nollau P; Ziermann J; Clement JH; La Rosée P; Hochhaus A; Butt E
Oncotarget; 2014 Jul; 5(14):5257-71. PubMed ID: 24913448
[TBL] [Abstract][Full Text] [Related]
19. Tyrosine phosphorylation of CRKL in Philadelphia+ leukemia.
ten Hoeve J; Arlinghaus RB; Guo JQ; Heisterkamp N; Groffen J
Blood; 1994 Sep; 84(6):1731-6. PubMed ID: 7521685
[TBL] [Abstract][Full Text] [Related]
20. Modeling of molecular interaction between apoptin, BCR-Abl and CrkL--an alternative approach to conventional rational drug design.
Panigrahi S; Stetefeld J; Jangamreddy JR; Mandal S; Mandal SK; Los M
PLoS One; 2012; 7(1):e28395. PubMed ID: 22253690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
